Combination of gemcitabine and cisplatin for advanced non-small cell lung cancer: a phase II study with emphasis on scheduling (Q33338921)

25 July 2017

Combination of gemcitabine and cisplatin for advanced non-small cell lung cancer: a phase II study with emphasis on scheduling (English)

1 reference

25 July 2017

1 reference

G Giaccone

2

0 references

Pieter E Postmus

5

object named as

P E Postmus

1 reference

25 July 2017

C Huisman

1

1 reference

25 July 2017

C J van Groeningen

3

1 reference

25 July 2017

G Sutedja

4

1 reference

25 July 2017

E F Smit

6

1 reference

25 July 2017

1 August 2001

1 reference

25 July 2017

1 reference

25 July 2017

33

1 reference

25 July 2017

2-3

1 reference

25 July 2017

267-275

1 reference

Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines

25 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900187-8

7 January 2021

Scheduling of gemcitabine and cisplatin in Lewis lung tumour bearing mice

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900187-8

7 January 2021

Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900187-8

7 January 2021

Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900187-8

7 January 2021

Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900187-8

7 January 2021

Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: interim analysis of a phase III trial of the Southern Italy Cooperative Onc

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900187-8

7 January 2021

Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900187-8

7 January 2021

Weekly gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900187-8

7 January 2021

Monthly gemcitabine (days 1, 8 and 15) plus cisplatin (days 1-3) in advanced non-small cell lung cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900187-8

7 January 2021

Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900187-8

7 January 2021

Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900187-8

7 January 2021

Phase II trial assessing the combination of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC).

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900187-8

7 January 2021

A phase II study of a novel gemcitabine plus cisplatin regimen administered every three weeks for advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900187-8

7 January 2021

Gemcitabine and cisplatin as induction regimen for patients with biopsy-proven stage IIIA N2 non-small-cell lung cancer: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group (EORTC 08955).

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900187-8

7 January 2021

Gemcitabine-cisplatin: a schedule finding study.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900187-8

7 January 2021

10.1016/S0169-5002(01)00187-8

Identifiers

DOI

1 reference

25 July 2017

1 reference